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Summary: A new photometric assay for factor XIII was evaluated for its analytical performance and clinical
usefulness. The test showed good performance characteristics: intra-assay coefficients of variation between
0.83 and 2.68%, inter-assay coefficients of variation from 3.4 to 4.5%. The test can be conducted rapidly on
an automated analyser such as the Cobas Bio®. The reference values (mean ± 2 SD) ranged from 67 to 147%
and there was no gender difference. The comparability of the photometric test with a clot lysis factor XIII
test showed an acceptable coefficient of correlation r = 0.87 (p < 0.0001). The diagnostic conformity of both
tests was 76.7%. Factor ΧΠΪ concentrations were assessed in seven patient groups. In liver cirrhosis, M.
Crohn and during pregnancy noticeable percentages of lowered values were found: i.e. 18.2%, 11.8% and
10.0% respectively. Elevated values were seen in hypertensive patients (16%) and in the small group of
patients with carcinoma of the ovarium (22.2%). These results show that the incidence of acquired factor
XIII deficiencies is relative low. The clinical meaning of reduced or enhanced factor XIII needs to be clarified
by more extensive patient studies.
Introduction
Coagulation factor ΧΠΙ is a zymogen (proenzyme),
present in the circulation, which is transformed into
its active form (factor Xllla) by the proteolytic attack
of thrombin in the presence of Ca2+. It is a transglu-
taminase (EC 2.3.2.13) catalysing an acyl transfer
reaction. When a peptide-bound lysine residue is the
acyl receptor, it cross-links two pep tide chains (1).
The best known function of factor XIII is the cross-
linking of fibrin to produce insoluble fibrin polymers
(2). It simultaneously incorporates ot2-antiplasmin into
fibrin, thereby reducing the initial fibrinolytic activity
(3). Moreover, factor XIII promotes the cross-linking
of a fibronectin with fibrin (3). The interaction of
factor XIII with collagen results in an acceleration of
wound healing (4) and stimulates fibroblast prolifer-
ation (5, 6). In addition to its presence in plasma,
factor XIII also occurs in platelets and placenta.
Thrombocytic and placenta) factor XIII might be
identical (7). Plasmatic factor XIII consists of two
"A" subunits complemented with a S unit, whereas
thrombocytic and placental factor XIII consist of two
subunits "A" (8). Many attempts have been made to
determine factor XIII and to introduce such deter-
minations into laboratory diagnosis. For this purpose,
several assays for factor XIII have been developed
(9 — 20). Most of them, however, are troublesome,
Factor XIII
Thrombin,
Factor Xllla
Specific peptide + Glycine-ethylester| Factor Xllla
Peptide-Glycine-ethylester + NH3
NH3 + oc-keloglutarate + NADH + H+| Ghitamate dehydrogenase
Glutamate + NAD+
Fig. 1. Principle of the photometric factor XIII assay (The
specific peptide is composed of ten amino acids with
the sequence Leu-Gly-Pro-Gly-Gln-Ser-Lys-Val-Ile-
Gly-amide).
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poorly reproducible, time consuming and not suitable
for automation. Recently the Behring Corporation
developed a new assay for factor XIII activity meas-
urement. The principle of the assay (see fig. 1) is the
release of ammonia when factor XHIa catalyses the
coupling of glycine-ethylester with a new specific de-
kapeptide with a C-terminal amide group. The am-
monia formed is determined from the decrease in
absorbance at 340 nm due to dehydrogenation of
NADH in the presence of glutamate dehydrogenase
(EC 1.4.1.4) and 2-oxoglutarate. A peptide clot inhib-
itor is added to avoid interference due to gelation of
the test mixture (21). In the present study we evaluated
the analytical performance of the test, and applied it
to a group of healthy volunteers and several patient
groups.
Tab. 1. Cobas Bio measuring conditions for the photometric
factor XIII assay.
1 Units
2 Calculation factor
3 Standard 1 cone
4 Standard 2 cone
5 Standard 3 cone
6 Limit
7 Temperature (°Q
8 Type of analysis
9 Wavelength (nm)
10 Sample volume (μί)
11 Diluent volume (μί)
12 Reagent volume (μί)
13 Incubation time (s)
14 Start reagent volume (μί)
15 Time of first reading (s)
16 Time interval (s)
17 Number of readings
18 Blanking mode
19 Printout mode
Own
0
99
99
99
0
37.0
2
340
25
10
250
180
0
300.0
30
10
1
2
Materials and Methods
Samples
Venous blood samples were collected from subjectively healthy
individuals and from patients between 8.30 and 9.00 h. Citrated
plasma was prepared by centrifuging 9 volumes of freshly drawn
blood with 1 volume of trisodium citrate (0.11 mol/1) for 20
min at 1800#. The plasma was used immediately or stored at
— 70 °C in plastic tubes and thawed with tap water at 37 °C
for 5 min before use.
Methods
For the quantitative factor XIII assay we used the test kit of
Behring (Marburg, Germany). For comparison purposes we
performed the clot lysis assay according to Karges (l), also
purchased from Behring (Marburg, Germany). The results of
the clot lysis test are given as the highest dilution (range 25%
to 200% in steps of 25%) of plasma with a lysis resistant clot
residue.
Test procedure
The determinations were performed on a Cobas Bio® centrif-
ugal analyser (Hoffmann La Roche, Basel, Switzerland). The
measuring conditions for the Cobas Bio are given in table 1.
Patients
The reference range was determined on 102 subjectively healthy
volunteers (age range 20-50 years, mean age 38 years. The
test was also performed on patients with liver cirrhosis (n = 25),
patients with M. Crohn in the phase of exacerbation (n = 22),
and on patients with hypertension (n = 51), with carcinoma of
the lung (n = 48), of the colon (n = 23), of the ovarium
(n = 9), and during pregnancy (n = 56). The same patients
have been described in detail elsewhere (22-26).
The patients with liver cirrhosis consisted of nine patients with
Child-Turcotte classification A, nine patients with Child-Tur-
cotie classification B and 7 patients with Child-Turcotie classi-
fication C. The patients with M. Crohn had a "van Hees"
activity index ranging from 210—313.
The hypertension patients consistently showed raised blood
pressures: the diastolic pressure ranged between 90 and 144
mmHg; the systolic pressure varied from 130-200 mmHg.
The carcinoma patients were untreated and recently diagnosed.
The gestation periods of the pregnant women varied from 6—40
weeks (mean 25.1 weeks).
Results
Reproducibility was tested at different factor XIII
concentrations with samples obtained by mixing
pooled normal plasma and factor Xlll-deficient
plasma or saline. The intra-assay coefficient of vari-
ation ranged from 0.83 to 2.68% depending on the
tested concentration. The inter-assay coefficient of
variation was 3.4% (at 95.8% factor XIII) and 4.5%
at 55.1% factor XIII (see tab. 2).
Tab. 2. Reproducibility of the factor XIII assay (n.d. = not
done).
F XIII Intra-assay
concentration · -
(%) CV
120.0
91.7
53.3
39.1
0.83
1.35
2.68
1.08
n
20
20
20
20
F XIII Inter-assay
concentration
(%) CV
n.d.
95.8
55.1
n.d.
n.d.
3.4
4.5
n.d.
n
10
10
—
Table 3 contains a contingency table of the photo-
metric factor XIII results in comparison with those
of the clot lysis factor XIII assay. Diagnostic confirm-
ity was 76.7%. A Spearman rank coefficient of cor-
relation was calculated of r = 0.87; p < 0.0001.
The reference values (tab. 4) were calculated from 102
subjectively healthy individuate(46 mates, 56 females).
No differences were seen between the sexes. The av-
erage value was 107%, the median value 104%. Since
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Tab. 3. Diagnostic conformity (76.7%) of the photometric and the clot lysis factor XIII tests (n = 155).
Number of samples at each factor XIII concentration
determined by clot lysis
Number of samples
at each factor XIII concentration
determined by the photometric assay
0- 75%
75-150%
>150%
0-75%
8
0
0
75-125%
20
107
0
125-200%
0
16
4
Tab. 4. Basic statistics and reference range of a group of healthy
volunteers.
Factor XIII
plasma
concentration
Average
Median
Standard deviation (SD)
Lower quartile
Upper quartile
Interquartile range
107%
104%
20%
91%
123%
31%
Reference range
(mean ± 2 SD)
67-147%
the distribution was Gaussian, the reference values
were taken as mean value ± 2 SD i.e. 67 — 147%.
In table 5 the results of the factor XIII concentrations
in different disease states are given. High percentages
of low values were found in liver cirrhosis (18.2%),
M. Crohn (11.8%), carcinoma of the ovarium (22.2%)
and during pregnancy (10.0%). High proportions of
elevated values were seen in hypertensive patients
(16%) and in carcinoma of the ovarium (22.2%).
Discussion
The newly available kinetic factor XIII assay showed
good reproducibility, comparable to that reported in
the literature (27). Comparability with a clot stability
test was also satisfactory and in close agreement with
other results (27). The reference values were also in
concordance with those reported in the literature (27).
The new test shows good performance characteristics;
it is also rapid, easy to perform and shows good
reproducibility. With regard to the clinical usefulness
of the test, we know from the literature that a con-
genital factor XIII deficiency is the exception, whereas
the acquired form is relatively common. As early as
1972, a substantial decrease was reported in patients
with acute leukaemia (28). Another case of factor
XIII deficiency was reported in 1982 by Kuratsuji et
al. (29) in antibiotic-associated pseudo-membranous
colitis. A successful pregnancy of a woman with con-
genital factor XIII deficiency treated with substitutive
therapy has been described by Rodeghiero et al. (30)
and Boda et al. (31). Several studies have dealt with
low factor XIII concentrations in Crohn's disease (32)
and colitis ulcerosa (33) and the treatment of patients
suffering from these diseases with factor XIII concen-
trate (34, 35). Most recently, factor XIII deficiencies
were reported in systemic haematological disorders,
morbus Schönlein Hennoch and bacterial infections,
as well as in inflammatory bowel disease (36). Re-
garding the clinical usefulness of the test, we conclude
from the results of the present study that the photo-
metric factor XIII test is useful for the detection of
moderate deficiencies as established in patients with
Tab. 5. Values for factor XIII in several patient groups.
Patient groups F XIII concentrations (%)
SD Min Max FXIII FXIII
decreased1) increased2)
Liver cirrhosis
M. Crohn in acute phase
with thrombocytosis
Hypertension
Carcinoma of the lung
Carcinoma of the colon
Carcinoma of the ovarium
Pregnancy
(n = 25)
(n = 22)
(n = 51)
(n = 48)
(n = 23)
(n = 9)
(n « 56)
97.0
100.0
110.6
104.4
102.7
110.1
93.7
29.6
22.1
24.6
26.4
17.8
39.9
19.6
36
47
72
58
65
56
54
166
136
173
163
146
183
136
18.2
11.8
9
4.7
4.3
22.2
10.0
3.0
0
16.0
7.0
4,3
22.2
0
') percentage of values beneath the lower limit of the reference range.
2) percentage of values above the upper limit of the reference range.
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liver cirrhosis, morbus Crohn and during pregnancy.
It must be considered that the evaluation of protein
changes during pregnancy is complicated by the re-
distribution of body water with increasing gestational
age, which might cause a lowering of protein concen-
trations. In the present study, however, factor XIII
did not show a significant decrease with ongoing
pregnancy (r = —0.026, n.s.). Nevertheless, lowered
factor XIII during pregnancy may be partly due to
the described effect.
The detection of elevated factor XIII might also be
of clinical value, e. g. in hypertensive patients and
perhaps in patients with carcinoma of the ovarium,
although this group is too small to draw definitive
conclusions. The demonstrated incidence of decreased
or increased values, however, seems to be relatively
low. The clinical significance of the observed raised
or lowered factor XIII values is therefore not clear.
More extensive clinical studies are required to address
these issues.
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